Stock Track | United Therapeutics Plummets 7.19% Intraday on Tyvaso Revenue Miss

Stock Track

Feb 27

United Therapeutics' stock plummeted 7.19% during intraday trading on Thursday, as the company reported fourth-quarter revenue for its Tyvaso franchise and Tyvaso dry powder inhaler that fell short of market expectations.

Despite overall revenue growth to $790.2 million from $735.9 million a year earlier and earnings per share increasing to $7.70 from $6.19, the miss in key product lines weighed on investor sentiment. The company also announced development of a soft-mist inhaler for Tyvaso, which could improve market share upon potential launch in 2027, but this longer-term positive was overshadowed by the immediate revenue disappointment.

Analysts from RBC Capital Markets noted the revenue miss but raised their price target on the stock to $643 from $587, maintaining an Outperform rating, citing the potential of the new inhaler technology.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175787719"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175787719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175787719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175787719","market":"nz","top_or_hot":-1,"title":"Stock Track | United Therapeutics Plummets 7.19% Intraday on Tyvaso Revenue Miss","media":"Stock Track","content":"<p>United Therapeutics' stock plummeted 7.19% during intraday trading on Thursday, as the company reported fourth-quarter revenue for its Tyvaso franchise and Tyvaso dry powder inhaler that fell short of market expectations.</p><p>Despite overall revenue growth to $790.2 million from $735.9 million a year earlier and earnings per share increasing to $7.70 from $6.19, the miss in key product lines weighed on investor sentiment. The company also announced development of a soft-mist inhaler for Tyvaso, which could improve market share upon potential launch in 2027, but this longer-term positive was overshadowed by the immediate revenue disappointment.</p><p>Analysts from RBC Capital Markets noted the revenue miss but raised their price target on the stock to $643 from $587, maintaining an Outperform rating, citing the potential of the new inhaler technology.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | United Therapeutics Plummets 7.19% Intraday on Tyvaso Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | United Therapeutics Plummets 7.19% Intraday on Tyvaso Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 01:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>United Therapeutics' stock plummeted 7.19% during intraday trading on Thursday, as the company reported fourth-quarter revenue for its Tyvaso franchise and Tyvaso dry powder inhaler that fell short of market expectations.</p><p>Despite overall revenue growth to $790.2 million from $735.9 million a year earlier and earnings per share increasing to $7.70 from $6.19, the miss in key product lines weighed on investor sentiment. The company also announced development of a soft-mist inhaler for Tyvaso, which could improve market share upon potential launch in 2027, but this longer-term positive was overshadowed by the immediate revenue disappointment.</p><p>Analysts from RBC Capital Markets noted the revenue miss but raised their price target on the stock to $643 from $587, maintaining an Outperform rating, citing the potential of the new inhaler technology.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"","article_id":"1175787719","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175787719","pubTimestamp":1772127539,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"United Therapeutics' stock plummeted 7.19% during intraday trading on Thursday, as the company reported fourth-quarter revenue for its Tyvaso franchise and Tyvaso dry powder inhaler that fell short...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"个股追踪|Tyvaso营收未达预期United Therapeutics盘中暴跌7.19%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"United Therapeutics' stock plummeted 7.19% during intraday trading on Thursday, as the company reported fourth-quarter revenue for its Tyvaso franchise and Tyvaso dry powder inhaler that fell short of market expectations.Despite overall revenue growth to $790.2 million from $735.9 million a year earlier and earnings per share increasing to $7.70 from $6.19, the miss in key product lines weighed on investor sentiment. The company also announced development of a soft-mist inhaler for Tyvaso, which could improve market share upon potential launch in 2027, but this longer-term positive was overshadowed by the immediate revenue disappointment.Analysts from RBC Capital Markets noted the revenue miss but raised their price target on the stock to $643 from $587, maintaining an Outperform rating, citing the potential of the new inhaler technology.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}